VP Manufacturing/CTO - Cell & Gene Therapy

VP Manufacturing/CTO - Cell & Gene Therapy

Job Title: VP Manufacturing/CTO - Cell & Gene Therapy
Contract Type: Contract
Location: United Kingdom
Salary: Competitive
Start Date: 2020-06-18
Reference: V-46189
Contact Name: Steve Smith
Contact Email:
Job Published: June 19, 2020 15:37

Job Description

In response to the LifeArc/MRC call for bids to address the industry’s gene therapy manufacturing bottleneck on 4th May; brand news plans are underway to design and build a brand new state-of-the-art facility as part of an academia/industry collaboration.


Led by a recognised cell & gene therapy academic KOL; a strategically considered location and land has already been acquired, with early plans drawn up for the new facility. It will act as a bioaccelerator hub to serve drug discovery through to clinical trials and commercialisation for both internal and external projects.


Therefore, this brand new Contract Manufacturing Organisation(CMO) is now looking to hire their first industry-experienced Cell & Gene Therapy Manufacturing Consultant to assess the feasibility and development of the new facility design and support the bid due in September 2020.


The person will have significant experience designing and implementing gene therapy manufacturing facilities/workflows, considering where they are now and what things need to be implemented to achieve immediate goals as well as future proofing the business. This will include recommendation of the latest cutting-edge technologies and consulting on what is required to scale up the business in line with industry demand.


Expected hours will be between 1-3 days per week until the September bid deadline. This could be a consulting only role or part-time to perm depending on personal circumstance and ambitions. For more senior applicants this could also offer the potential of a Director/VP Manufacturing/Chief Technology Officer opportunity with a view to becoming the CEO, if desired.


For more information please contact Steve Smith, Head of Rare Disease and Cell & Gene Therapy:


I look forward to hearing from you.